The effect of MYB variants on blood cancers and their treatment outcom
Research type
Research Study
Full title
How do inherited variations affecting MYB protein activity influence Haematopoietic Stem Cells and the outcomes of transplantation therapies?
IRAS ID
361028
Contact name
Graham Caine
Contact email
Sponsor organisation
NHSBT
Duration of Study in the UK
0 years, 11 months, 31 days
Research summary
The haematopoietic stem cell (HSC) sits at the top of a hierarchy of differentiation that maintains blood cell production throughout life and is the basis of transplantation therapies in many clinical contexts, not least of which is the treatment of haematological malignancy. The properties of HSC are dictated by a combination of cell intrinsic and extrinsic factors acting on gene expression, such that a network of multiple transcription factors creates a gene regulatory landscape within the HSC that is able to respond to changing external demands for blood cell production. A small number of key proteins act as critical nodes within this network, one example of which is the transcription factor MYB. The Frampton group has been studying the role of MYB for the last three decades both in the context of normal HSC function and the initiation and maintenance of haematological malignancy.
REC name
North East - York Research Ethics Committee
REC reference
25/NE/0177
Date of REC Opinion
15 Sep 2025
REC opinion
Favourable Opinion